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Abstract: The peroxisome proliferator-activated receptors (PPARs) function as ligand-activated
transcription factors that convert signals in the form of lipids to physiological responses through the
activation of metabolic target genes. Due to their key roles in lipid and carbohydrate metabolism,
the PPARs are important drug targets. However, for several of the PPAR drugs currently in use,
adverse side effects have been reported. In an effort to identify compounds from marine organisms
that may serve as molecular scaffolds for the development of novel and safer PPAR-targeting drugs,
we performed a bioassay-guided screening of organic extracts made from organisms supplied by
the Norwegian Biobank of Arctic Marine Organisms (Marbank). Among several interesting hits,
we identified two poorly described isomeric oxo-fatty acids from the microalgae Chaetoceros karianus
for which we provide the first evidence that they might display dual specificity towards human
PPARα and PPARγ. Principal component analysis showed that C. karianus stood out from other
Chaetoceros species, both with respect to the metabolic profile and the PPAR activity. The isolation of
these compounds holds the potential of uncovering a PPAR pharmacophore with tunable activity
and specificity.
Keywords: PPAR; dual agonist activity; metabolomics; Chaetoceros karianus; LC-MSe; NMR
1. Introduction
The peroxisome proliferator-activated receptors (PPARs) are operating as lipid sensing receptors
at the crossroads between carbohydrate and lipid homeostasis, and metabolic disorders. Functioning
as ligand-activated transcription factors, they integrate signals in the form of lipids (fatty acids,
phospholipids, eicosanoids, and other oxygenated fatty acids) to physiological responses through the
activation of metabolic target genes [1,2]. A first step in this process is the binding of lipid ligands
to the PPAR ligand-binding domain (LBD) [3,4]. In humans, the PPAR isoforms PPARα and -γ
are mainly expressed in liver and adipose tissue, respectively, while PPARδ is more ubiquitously
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expressed [1,5]. When PPARγ is ligand-activated it induces adipocyte growth and differentiation by
transcriptionally regulating target genes involved in lipogenesis and lipid storage [6–8]. Moreover,
the activation of PPARγ maintains normal insulin sensitivity through upregulation and secretion of
adipokines such as adiponectin and leptin from adipose tissue [9]. In parallel, PPARα increases lipid
uptake and energy expenditure in the liver by upregulating targets involved in fatty acid transport,
activation, and oxidation [10,11]. Altogether this protects the organism against high levels of circulating
triacylglycerols and harmful free fatty acids [12] and ensures normal insulin function in peripheral
tissues [9]. However, when adipose tissue increases past critical mass, it attracts immune cells like NK
cells and macrophages, and starts to secrete pro-inflammatory cytokines like tumor necrosis factor
alpha (TNF-α), interleukin-1 beta (IL-1β), and resistin, which results in suppressed insulin action and
increased low density lipoprotein (LDL)-cholesterol [13–16]. Liver steatosis is another detrimental
condition, fueled by PPARγ during a high-fat state [17]. This leads to reduced fatty acid oxidation and
ultimately liver failure, which together with the adverse adipokine secretion exacerbates obesity.
With their key roles in lipid and sugar metabolism, the PPARs have for many years been top
priority drug targets [18]. Consequently, several PPAR ligands with well-recognized biological effects
are in clinical use, like the hypolipidemic fibrates, acting as PPARα activators, and the anti-diabetic
thiazolidinediones (TZDs), targeting PPARγ [19,20]. However, adverse side effects have been reported,
especially for the TZDs [21,22]. One way to avoid these problems has been to find or design partial [23,24]
or dual [25,26] agonists which in general seems to come with fewer side effects. Thus, the aim of the
present work was to identify compounds from marine organisms that regulate PPAR activity, and that
may serve as molecular scaffolds for the development of novel, safer PPAR-targeting drugs.
The diatom genus Chaetoceros contributes heavily to the overall primary production in the northern
and Arctic seas [27,28]. Northern diatoms are characterized by potentially high chemical diversities
and bioactivity levels [29,30]. Several species from this genus, kept in stock cultures by the Norwegian
Biobank of Arctic Marine Organisms (Marbank, www.imr.no/marbank/en), were used as a library in
the bioassay-guided screening for PPAR ligands reported herein. In the present study we identified
two poorly described, closely related oxo-fatty acids (Figure 1) from the diatom Chaetoceros karianus
with an apparent dual specificity towards human PPARα and PPARγ. The isolation of these isomeric
compounds with dual PPAR α/γ agonist activity holds the potential of uncovering a pharmacophore
with tunable activity and specificity.
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The main goal of  this  study was  to  identify novel PPAR agonists or modulators  from arctic 
marine  organisms.  Any  such  hit  compound  might  later  form  the  basis  of  a 
structure‐activity‐relationship  (SAR)  effort,  where  the  aim  would  be  to  develop  drugs  for  the 
treatment  of diabetes  and metabolic  syndrome. To  this  end, we  performed  a  primary  screening 
where we transiently expressed Gal4‐LDB constructs comprising the ligand binding domain (LBD) 
Figure 1. Chemical structures of the two isolated oxo-fatty acids, (7E)-9-oxohexadec-7-enoic acid (1)
and (10E)-9-oxohexadec-10-enoic acid (2).
2. Results and Discussion
The main goal of this study was to identify novel PPAR agonists or modulators from arctic marine
organisms. Any such hit com ound might later form the basis of a s ructure-activity-relationship
(SAR) ffort, where the aim would be to develop drugs for the treatment of diabetes and metabolic
syndrome. To this end, we performed a primary screening where we transiently expressed Gal4-LDB
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constructs comprising the ligand binding domain (LBD) of human PPARα, -γ, and -δ fused to the
yeast Gal4 DNA-binding domain in COS-1 cells, a fibroblast-like cell line derived from monkey
(Cercopithecus aethiops) kidney. Testing of hundreds of extracts (40 mg/mL) from Marbank in the
cell assay system allowed us to identify and confirm the PPAR modulatory activity from a diverse
set of organisms (Table S1). The diatom species Chaetoceros karianus (M11031) interestingly showed
a consistent activation of PPARα and -γ. Importantly, the same extracts were not able to activate
human PPARδ, or human Liver X receptor (LXR) α or -β (not shown).
To verify the findings from C. karianus, Flash chromatography fractions of fresh materials from
the Marbank were prepared as described in the experimental section by reconstituting organic extracts
in ACN/H2O, defatting with hexane, reconstituting in ACN/H2O, and eluting from a reverse-phase
C18 solid phase extraction (SPE) column. The new eluates (100 mg/mL) were used to stimulate COS-1
cells, this time expressing full-length human PPARα or -γ together with retinoic acid X receptor alpha
(RXRα), the natural PPAR heterodimerization partner. Gene activation was assessed on Luciferase
reporters driven by natural promoters; human CPTA1 for PPARα and human PLIN1 for PPARγ.
As demonstrated (Figure 2A,B), the C. karianus extract was able to activate both promoters. When
using reporters with mutated PPAR recognition elements (PPREs), the extract’s ability to activate was
significantly reduced (Figure 2C,D), corroborating PPAR-dependent agonism.
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fractions  of  60  s  each)  is  shown  in  Figure  3A. The  activity was  found  in  the  fractions  collected 
Figure 2. Concentration-dependent activation of natural peroxisome proliferator-activated receptor
(PPAR) target gene promoters using solid phase extraction (SPE) eluates from Chaetoceros karianus.
Monkey kidney fibroblasts, COS-1 cells, were transfected with plasmids expressing human, full-length
PPARα, retinoic acid X receptor alpha (RXRα), and a CPT1A promoter-driven luciferase reporter
(A) or with a CPT1A reporter with PPAR response elements (PPREs) mutated (C). Correspondingly,
cells were transfected with plasmids expressing human, full-length PPARγ and RXRα and a PLIN1
promoter-driven luciferase reporter (B) or with a PLIN1 reporter with PPREs mutated (D). Cells were
treated with a dilution series of SPE eluates (100% ACN). 1:1 dilution corresponds to ~100 µg dry
weight/mL. The results represent mean relative light units (RLU) ± s.d. of two independent assays
performed in duplicate. The activities of the positive controls (Rosiglitazone or Bezafibrate) were set to
100%. D: DMSO, B: 50 µM Bezafibrate, R: 1.0 µM Rosiglitazone.
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In order to track the activity found in the extract, we developed a HPLC-based activity profiling
protocol (see Experimental section). The chromatogram (210–600 nm) of a semi-preparative HPLC
separation (1.25 g extract) and the corresponding activity profile of the time-based fractionation
(40 fractions of 60 s each) is shown in Figure 3A. The activity was found in the fractions collected
between 14 and 22 min (Figure 3A). The pooled fractions of several injections were concentrated and
a second semi-preparative HPLC separation based on peak signal absorption at 227 nm was applied
(Figure 3, insert). The major peak of activity was found in fractions 10, 11, and 12 (Figure 3B,C). A dual,
yet weakly isoform-specific, agonist activity profile was observed, where fractions 10 and 11 increased
PPARα activation over the solvent controls by 224 and 167%, respectively, and fractions 10, 11, and 12
increased PPARγ activation by 175, 388, and 211%, respectively. All the remaining fractions showed












Panel  (A)  shows  a  representative  HPLC  chromatogram  (210–600  nm)  of  a  semi‐preparative 
separation of 1.2 g microalgal  extract. The  activity was  initially  found  in  the  squared  area  in  the 
time‐based fractionation. The insert shows part of a peak‐based separation for final purification. The 
HPLC‐based  activity  profiling  for  PPARα  (B)  and  PPARγ  (C)  receptor modulatory  activity  are 
shown above the chromatogram. The activities of the positive controls (Rosiglitazone or Bezafibrate) 
were set to 100%.   
Isolation  of  the  two  active  compounds,  1  and  2, was  achieved  by  reverse‐phase  SPE  and 
subsequent purification with semi‐preparative HPLC. The compounds were tracked with the aid of 
ultra‐performance  liquid chromatography‐electrospray  tandem mass spectrometry  (UPLC‐ESIMS) 
and photodiode array detection (UPLC‐PDA). In Figure 4A,B, typical base peak chromatograms of 
an SPE eluate, acquired  in both positive and negative mode, are  shown. The defatting  step with 
hexane removed apolar  lipids  that might  interfere with our screening system, while  the SPE step 
was designed  to  retain polar molecules  and peptides, which were not of  interest  in our nuclear 




Figure 3. HPLC-based PPAR activity profiling of an acetonitrile/H2O extract of Chaetoceros karianus.
Panel (A) shows a representative HPLC chromatogram (210–600 nm) of a semi-preparative separation
of 1.2 g microalgal extract. The activity was initially found in the squared area in the time-based
fractionation. The insert shows part of a peak-based separation for final purification. The HPLC-based
activity profiling for PPARα (B) and PPARγ (C) receptor modulatory activity are shown above the
chromatogram. The activities of the positive controls (Rosiglitazone or Bezafibrate) were set to 100%.
Isolation of the two active co , 1 and 2, was achieved by reverse-phase SPE and
subsequent purification i-preparative HPLC. The compounds were tracked with the aid
of ultra-performance liquid chromatography- lectrospray tande ma s spectrometry (UPLC-ESIMS)
and phot diode array detectio ( - ). In Figure 4A,B, typical base peak chromatograms of
an SPE eluate, acquired in both positive and negative ode, are shown. The defatting step with
hexane removed apolar lipids that might interfere with our screening system, while the SPE step was
designed to retain polar molecules and peptides, which were not of interest in our nuclear receptor
screen, as they translocate poorly to the cell nucleus and rarely have been reported to activate PPARs.
As shown in Figure 4A,B, the isolated compounds ionize differently in positive and negative mode
and appeared to not be the main components of the fraction mixture based on MS signal intensities.




Figure  4.  Ultrahigh  performance  liquid  chromatography‐electrospray  ionization  base  peak 
chromatograms of a solid phase extraction (SPE) eluate generated from culture extracts of Chaetoceros 
karianus in (A) positive mode (UPLC‐ESI+) and (B) negative mode (UPLC‐ESI−). Insert: Extracted ion 
chromatograms of  the most  intense  ions, m/z 251.2  [M + H − H2O]+  in positive mode  (A) and m/z 
267.2 [M − H]− in negative mode (B). 
High‐resolution mass  spectrometry  (HRMS) was used  to  identify  the molecular weight  and 
thus  the molecular  composition  of  the  isolated  compounds.  Initial  studies  in  positive  ionization 
mode showed complex mass spectra for compounds 1 and 2, indicating that it was advantageous to 
apply both positive and negative mode ionization protocols. Upon positive ESIMS, ions tentatively 








The  two  isomers were  subsequently  determined  as  (7E)‐9‐oxohexadec‐7‐enoic  acid  (1)  and 
(10E)‐9‐oxohexadec‐10‐enoic acid (2) from the interpretation of one‐ and two‐dimensional NMR data 





absence  of  conjugation.  The HRMS/MS  spectra  of  the  two  structural  isomers  exhibited  several 
features that were of high diagnostic value. Most notably, fragment ions with m/z corresponding to 
[M – H − 44]− upon negative ionization and [M + H − 46]+ upon positive ionization are commonly a 




Figure 4. Ultrahigh performance liquid chromatography-electrospray ionization base peak
chro atogra s of a solid phase extraction (SPE) eluate generated fro culture extracts of Chaetoceros
karianus in (A) positive ode (UPLC-ESI+) and (B) negative ode (UPLC-ESI−). Insert: Extracted ion
chro atogra s of the most intense ions, m/z 251.2 [M + H − H2O]+ in positive mode (A) and m/z 267.2
[M − H]− in negative mode (B).
i -r l ti spectrometry (HRMS) was used to identify the molecular weight and thus
t e molecular composition of the isolated compounds. I itial studies in positive ionization mode
showed complex mass spectra for compounds 1 and 2, i icating that it w s advantageous to apply
both positive and negative mode ionization protocols. Upon positive ESIMS, ions tentatively identified
as [M + H]+ (m/z 269.2114 for 1; m/z 269.2 16 for ), as well as more prominent ions attributable to
sodium addition ([M + Na]+) and dehydration ([M + H − H2O]+, [M + H − 2H2O]+), were observed
(data no shown). In additio , diagn stic ions corresponding to [M + H − 46]+ attribut ble to the loss
of CH2O2 indicated the presence of a carboxylic gr up in the two molecules. Furth r st dies applying
negative ionization mode afforded pred minantly ions corresponding to [M − H]− (m/z 267.1966 for 1
and 2), thus confirming the identity of t e [M + H]+ ion. This allowed us to determine the molecular
for ula of the two compounds, which tur ed out to be C16H28O3 for both molecules, showing that
t ey were structural isomers with a number of ring double bond equivalents of three.
t is rs r s s tl t r i s ( )- - ec-7-enoic acid (1)
( )- - exadec-10-enoic acid (2) from the interpretati n of one- and two-dimensional NMR
data as well as HRMS and HRMS/MS spectra. Furthermore, the structure determination process s
ssist t s s rc s ( icti r f ri t r l r cts, .c t s .c ).
e c s ere isolated as colorless oils in quantities of 60 µg of co pound 1 (approx.
95 rit ) a 53 µ f c 2 (a r . 75 rit ). e s ectra f t c s
ere si ilar it a si le a s r ti a i ( max) at 227 n (1) and 226 (2) i icati t e
a se ce of conjugation. The HRMS/MS spectra of the two structural isomers exhibited several features
that were of high diagnostic value. Most notably, fragment ions with m/z corresponding to [M – H −
44]− upon negative ionization and [M + H − 46]+ upon positive i nization are c mmonly a result of
the loss of CO2 and H2O2, respectively, and indicated the presence of a carboxylic acid (Figure 5).
Furthermore, t e MS/MS spectra contained a series of ions typical for hydrocarbons (m/z 71, 85, 99),
and thus gave strong evidence for compounds 1 and 2 being fatty acid derivatives. The major fragment
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ions, however, were observed at m/z 127.1339 for 1 and m/z 123.1038 and 125.1191 for 2 (Figure 5),
indicating a structural feature in the central part of the hydrocarbon backbone that facilitates the









Detailed  analyses  of  one‐  and  two‐dimensional  NMR  data,  including  1H,  correlation 
spectroscopy  (COSY),  total  correlation  spectroscopy  (TOCSY),  selective  TOCSY  (SELTOCSY), 
gradient‐selected  heteronuclear  single  quantum  coherence  spectroscopy  (g‐HSQC), 
gradient‐selected heteronuclear multiple bond correlation  (g‐HMBC), HSQC‐TOCSY, and nuclear 
overhauser effect spectroscopy (NOESY) spectra determined  in CD3CN as well as the comparison 
with published spectral data  [31,32], afforded complete  1H and  13C assignments  for compounds 1 
and 2  (Table 1). The data showed  the presence of a  trans‐coupled  (3JH‐H = 15.9 Hz) pair of olefinic 
protons at 6.08/6.84 ppm in 1 and 6.08/6.85 ppm in 2. In both isomers the lower‐field olefinic proton 
(i.e.,  6.84  ppm  and  6.85  ppm) was  additionally  coupled  (3JH‐H  =  7.0 Hz)  to  a methylene  proton 
resonance at 2.22 ppm, while the higher‐field olefinic proton (i.e., 6.08 ppm) only showed weak 4JH‐H 
coupling  (1.5 Hz)  to  the  same methylene protons, but no  3JH‐H coupling  in addition  to  its olefinic 
neighbor. At the same time, the g‐HMBC spectra showed the presence of a carboxyl‐carbon at 175.0 





13C  1H 13C 1H
1  175.0, t  ‐  175.2, t  ‐ 
2  34.2, t  2.27, t, (7.4)  34.3, t  2.27, t, (7.5) 
3  25.6, t  1.57, m  25.6, t  1.57, m 
4  29.5, t  1.34, m  29.8, t  1.31, m, overlapped 
Figure 5. High-resolution mass spectrometry (HRMS/MS) spectra from fragmentations of [M − H]−
ions of (A) (7E)-9-oxohexadec-7-enoic acid (m/z 267.2139), (B) (10E)-9-oxohexadec-10-enoic acid (m/z
267.2164) and the assigned structurally informative fragmentations of these ions.
Detailed analyses of one- and two-dimensional NMR data, including 1H, correlation spectroscopy
(COSY), total correlation spectroscopy (TOCSY), selective TOCSY (SELTOCSY), gradient-selected
heteronuclear single quantum coherence spectroscopy (g-HSQC), gradient-selected heteronuclear
multiple bond correlation (g-HMBC), HSQC-TOCSY, and nuclear overhauser effect spectroscopy
(NOESY) spectra determined in CD3CN as well as the comparison with published spectral data [31,32],
afforded complete 1H and 13C assignments for compounds 1 and 2 (Table 1). The data showed the
presence of a trans-coupled (3JH-H = 15.9 Hz) pair of olefinic protons at 6.08/6.84 ppm in 1 and
6.08/6.85 ppm in 2. In both isomers the lower-field olefinic proton (i.e., 6.84 ppm and 6.85 ppm)
was additionally coupled (3JH-H = 7.0 Hz) to a methylene proton resonance at 2.22 ppm, while the
higher-field olefinic proton (i.e., 6.08 ppm) only showed weak 4JH-H coupling (1.5 Hz) to the same
methylene protons, but no 3JH-H coupling in addition to its olefinic neighbor. At the same time,
the g-HMBC spectra showed the presence of a carboxyl-carbon at 175.0 ppm (1) and 175.2 ppm (2),
as well as a carbonyl-carbon at 201.4 ppm (identical shift for both compounds).
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Table 1. 1H and 13C NMR data of compounds 1 and 2 (600/150 MHz in CD3CN, δ in ppm, J in Hz).
Position
1 a 2 a
13C 1H 13C 1H
1 175.0, t - 175.2, t -
2 34.2, t 2.27, t, (7.4) 34.3, t 2.27, t, (7.5)
3 25.6, t 1.57, m 25.6, t 1.57, m
4 29.5, t 1.34, m 29.8, t 1.31, m, overlapped
5 28.7, t 1.48, m 29.8, t 1.31, m, overlapped
6 33.0, t 2.22, ddt, (7.5, 7.0, 1.5) 29.8, t 1.31, m, overlapped
7 148.2, d 6.84, dt, (15.9, 7.0) 25.1, t 1.55, m
8 131.1, d 131.1, dt, (15.9, 1.5) 40.4, t 2.54, t, (7.4)
9 201.4, s - 201.4, s -
10 40.4, t 2.54, t, (7.4) 131.2, d 6.08, dt, (15.9, 1.5)
11 25.1, t 1.55, m 148.1, d 6.85, dt, (15.9, 7.0)
12 29.8, t 1.30, m 33.0, t 2.22, ddt. (7.5, 7.0, 1.5)
13 30.4, t 1.29, m 28.6, t 1.48, tt, (7.5, 7.5)
14 32.5, t 1.30, m 32.2, t 1.33, m
15 23.3, t 1.32, m 23.3, t 1.34, m
16 14.4, q 0.90, t, (7.0) 14.4, q 0.91, t, (7.0)
a chemical shifts, determined at 25 ◦C, are relative to internal CHD2CN (1.96 ppm) and CD3CN (118.26 ppm) [33].
The quantity of the isolated material was too low to obtain one-dimensional direct 13C-NMR data,
and the DEPT spectra only showed few 13C-resonances of low signal/noise. The carbonyl-carbon
showed 2JC-H and 3JC-H correlations in the g-HMBC spectra to a 3JH-H coupled methylene proton
resonance at 2.54 ppm (identical shift for both compounds) and the lower-field olefinic proton,
respectively. From these data it became clear that the carbonyl-function was interspersed between
the olefinic double bond and an aliphatic chain, i.e., the compounds contained an α,β-unsaturated
ketone. For further structure determination of compound 1, the assessment of the g-HSQC, g-HMBC,
and high-resolution COSY data clearly showed the presence of five methylene groups between the
carboxyl-carbon and the olefinic moiety, i.e., the molecule contained a 7,8-double bond. The exact
assignment of the methylene groups between the C-9 carbonyl and the terminal methyl group was
ambitious, as the protons of five of the six methylene groups appeared in a narrow window between
1.29 ppm and 1.32 ppm. Using high-resolution COSY data, it was possible to identify four of the six
methylene groups. Assignment of the remaining two methylene groups was only possible using the
HSQC-TOCSY experiment. This is a hybrid experiment that gives through-bond correlations between
a 13C-attached proton to all other coupled protons. The coupled protons can be seen along a line at
the same 13C chemical shift from the carbon atom attached to the primary proton (i.e., the HSQC
crosspeak). The assignment of the remaining methylene groups was then possible because individual
methylene groups were well resolved in the 13C dimension even though they overlapped in the 1H
dimension. NMR assignment of compound 2 started at the terminal methyl group. Long-range TOCSY
data (mixing time parameter d9 = 160 ms) showed a correlation between the methyl protons and the
olefinic protons, and hence these protons belonged to a common 1H spin system. Such a correlation
was absent in a TOCSY spectrum acquired using a mixing time of 80 ms. The assignment of the
methylene groups between the terminal methyl and the olefinic moiety was in this case ambitious
due to the fact that the NMR sample of compound 2 contained about 25% of compound 1. However,
careful examination of the g-HMBC, g-HSQC, SELTOCSY, and COSY data starting from the terminal
methyl group showed that compound 2 contained a 10,11-double bond, while the carbonyl group was
at the same position as in 1.
Mass spectrometry-aided structural elucidation of 1 and 2 was performed by interpreting HRMS
and HRMS/MS analyses of the isolated compounds (Figure 5). Compound 1 showed a fragmentation
pathway leading to an intense [M − 140]− fragment ion apparent at m/z 127.1339 (Figure 5A). This ion
is consistent with α-cleavage of the ketone across C8-C9, i.e., the bond joining the olefinic moiety in
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position C7-C8 with the carbonyl group at C9. Other minor fragments observed could be ascribed to
cleavage in activated sites within the aliphatic skeleton. The fragment ion at m/z 139.0935 [M − 128]−
is likewise consistent with cleavage across the C8-C9 bond, but with the charge on the other part of the
molecule (Figure 5A). The fragment ion at m/z 137.1195 could be explained by oxidation of the double
bond at the fragment ion m/z 139.0935 (Figure 5A). The location of the keto group in C-9 is confirmed
by the presence of the ion m/z 99.1036, consistent with α-cleavage of the ketone across the C9-C10 bond.
Other fragment ions of interest are m/z 85.1, consistent with a β-cleavage at the C10-C11 bond and the
fragment ion at m/z 153.1496 [M − 114]−, which could be ascribed to a cleavage of the bond adjacent to
the double bond at C7-C8 (Figure 5A). Another fragment ion observed at m/z 223.2269 [M− 44]− could
be ascribed to the loss of CO2, which is diagnostic for carboxylic acids such as fatty acids and fatty
acid derivatives. Compound 2 showed similar fragmentation pathways as compound 1 (Figure 5B),
with typical α-cleavages observed in oxo-fatty acids [34]. An intense fragment ion at m/z 125.1191 was
consistent with cleavage across C8-C9 (Figure 5B). Other important product ions were observed at m/z
97.0881 [M− 170]−, consistent with α-cleavage to the keto group across C9-C10, and the diagnostic ion
at 223.2280 [M− 44]−, consistent with the loss of CO2 (Figure 5B). The prominent m/z 123.1038 product
ion in the product ion spectrum of 2 could be the result of water loss from m/z 141.1503 (Figure 5B).
As hypothesized, based on the dereplication described above, the isolated compounds turned
out to be 9-oxohexadec-7-enoic acid (oxo-FA 1) (Figures 1 and 5A) and 9-oxohexadec-10-enoic
acid (oxo-FA 2) (Figures 1 and 5B). After establishing the structures of the two molecules 1 and
2, comprehensive literature searches revealed that the (E)-isomers of these molecules had recently
been described from other marine organisms [31,32]. In 2005 a new C16 fatty acid-based oxylipin
pathway was demonstrated in axenic cultures of the diatom Thalassiosira rotula, and compound 1
was isolated along with other novel oxo- and hydroxy unsaturated fatty acids, but no biological
activity was reported [31]. Compound 2 was isolated in a later study aimed at identifying
natural products with anti-inflammatory activity from the red algae Gracilaria verrucosa [32].
Compound 2 significantly inhibited the production of the pro-inflammatory mediators NO and
IL-6 in lipopolysaccharide-activated murine macrophage cells [32].
Having refined the oxo-fatty acids 1 and 2 to approximately 95% and 75% purity, respectively,
we wanted to reevaluate the weak PPAR isoform specificity observed during the bioassay-guided
isolation. To this end we treated COS-1 cells expressing Gal4-LBD chimeras with 100 µM of 1 and 2.
As can be seen in Figure 6, the dual PPARα/γ specificity profile was retained, while the potency was
somewhat reduced. Still, oxo-FA 1 seems to activate PPARγ slightly better than oxo-FA 2 (Figure 6B),
while the opposite is true for PPARα (Figure 6A). The low amount of material isolated (60 µg and
53 µg of oxo-FA1 and oxo-FA2, respectively) prevented further pharmacological characterization of
the two compounds. In a follow-up study, we intend to characterize the dose-response curves of
these oxo-fatty acids with respect to PPAR α/γ binding and confirm the functional activation of these
receptors by studying their PPAR-dependent regulation of relevant, endogenous target genes.
With their dual PPARα/γ specificity, these oxo-fatty acids might make a good start for
a structure-activity-relationship (SAR) study to identify PPAR-targeting anti-diabetic drug leads.
This could be achieved by comparing our oxo-fatty acids (1 and 2) with other cis- and
trans-hexadecenoic acids that do not possess the carbonyl group in their structure. Moreover,
the activity profile of the C. karianus oxo-fatty acids, as well as derivatives thereof, should be compared
with the profile of other promising dual PPARα/γ agonists, like Saroglitazar [35]. Saroglitazar is
marketed in Asia and displays significant improvement in both glycemic as well as dyslipidemic
parameters with no evidence of conventional side effects (as reviewed in [25]). From a structural
perspective, a recent study by Yore et al. [36] who made use of quantitative MS to identify metabolic
changes in transgenic Glut4 mice is highly interesting. Despite being obese, the studied animals showed
an increased glucose tolerance. Lipidomic analysis of their adipose tissue revealed the existence of
branched fatty acid esters of hydroxy fatty acids, so called FAHFAs. The most abundant form both in
mice and human white and brown adipose tissue is 9-PAHSA (palmitic acid-hydroxy stearic acid),
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having the hydroxyl/ester group placed on the same carbon as our 9-oxo-FAs. Even though the
PAHSAs signal through GPR120 to enhance insulin-stimulated glucose uptake, it could be possible
that the corresponding unbranded fatty acids (with the hydroxy-/keto group on C9) might have equally
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Figure 6. Dual PPARα/γ agonist activity with limited isoform specificity. COS-1 cells
transfected with a 5 × upstream activating sequence (5×UAS)-driven luciferase reporter and
(A) plasmids expressing yeast Gal4 DNA-binding fused to the ligand binding domain (LBD) of
human PPARα (Gal4-PPARα-LBD) or (B) PPARγ (Gal4-PPARγ-LBD) were treated with 100 µM
(7E)-9-oxohexadec-7-enoic acid (oxo-FA 1), 100 µM (10E)-9-oxohexadec-10-enoic acid (oxo-FA 2), 1 µM
Rosiglitazone (ROSI; PPARγ agonist), or 100 µM pirinixic acid (PIRI; PPARα agonist). The results
represent the mean RLU ± s.d. of two independent assays performed in quadruplicate.
Finally, to address whether the identified metabolite/activity profile is unique to the planktonic
diatom Chaetoceros karianus, we employed a metabolomics approach to compare it with different,
but related microalgae. Four additional strains of species belonging to the genus Chaetoceros were
obtained from the Marbank collection. Extracts and SPE eluates were generated from Cheatoceros
decipiens (M09048), Chaetoceros diadema (M09047), Chaetoceros furcellatus (M08023), Chaetoceros karianus
(M11031), and Chaetoceros socialis (M08009) as described in the Experimental section. To assess the
analogies and differences in the composition of the metabolites of the five species, a non-targeted
metabolite fingerprinting of SPE eluates was conducted. ACN/H2O-soluble constituents from these
species were analyzed by UPLC-HRESIMS as described in the Experimental Section. Results from
the UPLC-HRESIMS were further processed by peak picking and alignment for further Principle
Components Analyses (PCA). PCA demonstrated that striking differences exist between the metabolic
profiles of the five Chaetoceros species (Figure 7). Interestingly, the most distinct profiles were those
obtained from C. karianus and C. diadema.
When data obtained by UPLC-HRESIMS in positive ionization mode were subjected to principal
component analysis (PCA) (Figure 7A), it appeared that C. furcellatus and C. decipiens are similar
with regard to metabolite production. In positive ionization mode, the replicates were perfectly
clustered, indicating an appropriate method repeatability. Negative ionization mode data showed
similar clustering (Figure 7B), but in this case C. furcellatus and C. socialis were almost overlapping.
Both in positive and negative mode, it appeared that the metabolic profiles of C. furcellatus, C. decipiens,
and C. socialis were closely related. On the other hand C. karianus and C. diadema were less related to
the other three species and to each other with regard to metabolite production. In negative ionization
mode, the replicates were not as well clustered as in positive mode and showed some deviation
(Figure 7B). This somehow lower reproducibility could be attributed to instrumental drift and injection
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problems. Interestingly, and in line with the different metabolic profiles, the different Chaetoceros
extracts displayed different PPAR α/γ agonist activity (Figure 7C). Even though the relative position
of the species was shifted, the C. karianus PPAR α/γ activity was found to be high and at a distance
from both C. furcellatus and C. socialis, and C. diadema and C. decipiens which seemed to be more closely
related, respectively. Whether this is due to differences in oxo-fatty acid levels or different levels of
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(7E)-9-Oxohexadec-7-enoic acid (1) Colorless oil (60 µg). UV λmax (acetonitrile/H2O) 227 nm. Negative
HRESIMS m/z 267.1966; C16H28O3 requires m/z 267.1960. Positive high-resolution electrospray
ionisation mass spectrometry (HRESIMS) m/z 269.2114; C16H29O3 requires m/z 269.2117.
(10E)-9-Oxohexadec-10-enoic acid (2) Colorless oil (53 µg). UV λmax (acetonitrile/H2O) 226 nm. Negative
HR SIMS m/z 267.1966; C16H28O3 requi es m/z 267.1960. Positive HRESIMS m/z 269.2116; C16H29O3
requires m/z 269.21 7.
3. Materials and Methods
3.1. Biological Material
F r primary screening we used organic Flash fractions from the Marbank collection [37]. Inocula
for the mass cultivation of Chaetoceros karianus were from our in-house culture collection. The microalga
was isolated from north Norwegian spring bloom stocks in 2009. Mass cultivation was performed at
4.5 ◦C in a temperature and irradiation-controlled room, where the microalgae were grown in 0.3 m3
transparent plexiglas cylinders with external illumination. At the start of the culture period, mean
scalar irradiance across the cultivation cylinder was approximately 125 µmol m−2·s−1 and at the time
of harvesting it was approximately 35 µmol m−2·s−1 due to self-shadowing. The photoperiod was
14:10 (L:D). Illumination was supplied by Osram daylight fluorescent tubes.
The culture medium was Millipore filtered (0.1 µm) 33.5 ppt. seawater growth media with
a concentration of inorganic nutrients equivalent to f/10 (Sigma-Aldrich, St. Louis, MO, USA)
and a surplus of silicon (50 µmol). The growth rate of the cultures were monitored twice weekly
by measuring the in vivo fluorescence and by microscopic inspection of the cells. The biomass
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concentrations at the start of the experiments were approximately 2 µg·Chla·L−1 and by time of
harvested, approximately 350 µg·Chla·L−1. To monitor biomass development as Chla, a Turner
fluorometer (TD-700) was applied. The cells were harvested by sieving the culture though a 10 µm
mesh size plankton net, thus letting any (small) amounts of bacteria to be flushed out. After collection,
the cells were scraped off the plankton net and stored in 25 mL plastic tubes at −80 ◦C.
3.2. Bioassay-Guided Isolation Platform
3.2.1. General Extract Preparation
The samples were freeze-dried, ground, and stored at −20 ◦C before extraction with Milli-Q
water (2×, 24 h and 30 min, respectively) at 5 ◦C (20 mg/mL). The extracted slurries were then
centrifuged and the supernatant (the H2O extract) was removed. The pellet was then freeze-dried and
ground again.
To produce the organic extract, the pellet was extracted with MeOH/CH2Cl2 (1:1) (2× at 5 ◦C,
24 h and 30 min, respectively) making a 20 mg/mL organic extract. The extract was then filtered
through Whatman filters (nr. 3, Ø 125 mm) and the filtrate was evaporated in vacuo and stored at
−20 ◦C.
3.2.2. Specific Extract Preparation for Bioassay-Guided Fractionation
Organic extracts (0.5–2 g) from the library prepared as described above (Section 3.2.1) were
reconstituted in ACN/H2O (9:1) using an ultrasound bath (30 min) to make a 20 mg/mL suspension.
The suspension was then filtered, recovered in a separatory funnel, and defatted with hexane (1:1, 2×).
The polar organic extracts were evaporated to dryness and reconstituted in ACN/H2O (1:1), before
being subjected to vacuum-aided solid phase extraction (SPE) on Strata C18-E cartridges (Phenomenex,
Torrance, CA, USA). The eluates were recovered by a 5-fold concentration (100 mg/mL).
3.2.3. Semi-Preparative High-Performance Liquid Chromatography (Semiprep HPLC-PDA)
The SPE-eluates were subjected to semi-preparative reverse-phase chromatography on a Luna
C18 column (250 × 10 mm, 5 µm) (Phenomenex, Torrance, CA, USA). A 6 mL/min flow of a mobile
phase consisting of 0.1% formic acid (A) and 0.1% formic acid in acetonitrile (B) was employed with
gradient elution starting with 5% B, and rising to 100% B within 30 min. Then isocratic elution with
100% B was performed before switching back to the initial conditions. Time-based (60 s) fractions were
collected in a Waters 2767 sample manager after detection with a Waters 2998 PDA detector (Waters,
Milford, MA, USA). Fractions collected were then tested in our bioassay platform, and those showing
significant activity were pooled and subjected to a second round of semiprep HPLC-PDA. In this
second step, we applied a gradient elution program starting with 70% A (10 mM ammonium formate
and 0.1% formic acid) and 30% B (10 mM ammonium formate and 0.1% formic acid in acetonitrile),
rising to 100% B within 30 min. Then isocratic elution with 100% B was performed before switching
back to the initial conditions. Compounds 1 and 2 were collected in separate fractions by following the
PDA signal trace.
3.2.4. Plasmids
The pSG5-Gal4-hPPARα-LBD, pSG5-Gal4-hPPARδ-LBD, and pSG5-Gal4-hPPARγ-LBD encoding
Gal4 DNA-binding domain (DBD; aa 1–147) fused in frame with the SV40 nuclear localization signal 1,
and the ligand binding domain (LBD) of human PPARα (aa 168–468), PPARδ (aa 140–441), and PPARγ
(aa 205–505), respectively, were received as generous gifts from Dr. Krister Bamberg (AstraZeneca,
Mölndal, Sweden). The same was true for the pGL3-5×UAS-SV40 luciferase reporter consisting of
five Upstream Activation Sequences (UAS; 25 bp phasing) and a SV40 early promoter in front of the
Firefly Luciferase gene. The plasmid encoding full-length human PPARγ, pcDNA3.1-hPPARg2-FLAG,
was made by PCR amplification of human PPARG cDNA, using custom-made primers (harboring
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kozak and FLAG-tag), and subcloning it into pcDNA3.1(+) (Life Technologies, Carlsbad, CA, USA)
between NheI and NotI. The corresponding PPARα plasmid, pcDNA3.1-hPPARa-FLAG, was made
by PCR amplification of human PPARA cDNA and subcloning it into pcDNA3.1-hPPARg2-FLAG
between NheI and BamHI, exchanging PPARG with PPARA, and keeping the FLAG tag. The plasmid
encoding full-length human RXRα, pcDNA3-hRXRα, has been described earlier [38]. The human
PLIN1-driven reporters, pGL3-hPLIN1-3′del and pGL3-hPLIN1-3′del-PPREmut, have been described
before [7]. The human CPT1A-driven reporters, pGL3-hCPT1AInt and pGL3-hCPT1AInt-PPREmut,
were received as a gift from Prof. Diego Haro Bautista and have been described previously [39].
The vector pRL-CMV (Promega, Madison, WI, USA), constitutively expressing Renilla Luciferase,
was used as a control of transfection efficiency. All cloned plasmids have been sequenced. Cloning
primer sequences are available upon request.
3.2.5. Cell Culture, Transfection, and Luciferase Assays
COS-1 cells (ATCC® CRL-1650) were maintained in DMEM (Life Technologies, Carlsbad,
CA, USA) containing gentamicin (10 µg/mL) or penicillin/streptomycin (50 U/mL; 50 µg/mL)
and 10% fetal bovine serum (F7524; Sigma), at 37 ◦C in a humidified atmosphere of 5% CO2 in air.
Cell confluence never exceeded 80% before subculturing or transfection. For the screening campaign
the COS-1 cells were transiently transfected with 1.7 µg of the Gal4-PPAR-LBD expression plasmids
and 8.5 µg of the 5×UAS-SV40 luciferase reporter per 1 × 107 cells, using the Neon Transfection
System (Life Technologies, Carlsbad, CA, USA). The cells were then plated at 2 × 104 cells/well in
white 96-well plates (F96, Nalge Nunc Int., Rochester, NY, USA) and allowed to attach (5 h) before the
different fractions were added at two concentrations (final DMSO concentration of 0.35% or 0.70%).
Corresponding volumes of DMSO was used as the negative control. As positive controls, the following
synthetic agonist were used; PPARα: Bezafibrate (BM-15075; B7273, Sigma-Aldrich, St. Louis, MO,
USA) or Pirinixic acid (WY-14643; C7081, Sigma-Aldrich, St. Louis, MO, USA), PPARδ: GSK-516
(GW-501516; 43732, Sigma-Aldrich, St. Louis, MO, USA), and PPARγ: Rosiglitazone (BRL-49653;
Cayman Chemical, Ann Arbor, MI, USA). After 18 h the cells were washed with PBS, before D-luciferin
potassium salt dissolved in 30 mM HEPES (0.12 mg/mL), supplemented with 1 mM MgSO4 and
0.5 mM adenosine triphosphate was added directly to the wells (50 µL/well). Following 10 min
of incubation at room temperature, the emitted light signal was measured on an Envision reader
(PerkinElmer, Turku, Finland).
For the verification of hits, dose-response assays, and specificity assays, COS-1 cells were seeded
at 7 × 104 cells/well in 24-well plates. After 24 h, the cells were transfected with 0.1 µg of the
Gal4-DBD-PPAR-LBD expression plasmids, 0.2 µg of the 5×UAS-SV40 luciferase reporter, and 0.05 µg
of the Renilla Luciferase-coding internal control using Lipofectamin 2000 (Life Technologies, Carlsbad,
CA, USA). After 5 h, the fractions or semi-pure compounds in DMSO (final conc. 0.7%) were added
to the culture and the incubation continued overnight. After 18 h, the cells were washed in PBS and
lysed in Passive Lysis Buffer (Promega, Madison, WI, USA) and the Dual-Luciferase® ReporterAssay
System (Promega, Madison, WI, USA) was run on a Synergy 2 plate reader (BioTek, Winooski, VT,
USA) following the manufacturer’s protocol. The Firefly Luciferase readings were normalized to the
Renilla Luciferase numbers and data from at least two independent transfection experiments, run in
duplicate, are presented.
3.3. Structure Elucidation Platform
3.3.1. Ultra-Performance Liquid Chromatography Coupled to Data-Independent Mass Spectrometry
(UPLC-MSe)
High resolution mass spectra (UPLC-QToFMS) were recorded in positive and negative mode,
making use of both electrospray (ESI) and atmospheric pressure chemical ionization (APCI) interfaces
on a Xevo G2 QToF mass spectrometer (Waters, Milford, MA, USA). The following settings were
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applied in both ESI negative and ESI positive MS: Capillary voltage 0.5 kV, source and desolvation
temperatures of 130 ◦C and 400 ◦C, respectively, cone and desolvation gas at 20 L/h and 800 L/h,
respectively. The instrument was run in MSe resolution mode with a scan time of 0.1 s, centroid mode.
Low energy (no collision energy) and high energy (ramp collision energy from 30 to 50 V) spectra were
acquired in the mass range from m/z 100–1200. The instrument was regularly calibrated with sodium
formate with leucine enkephaline applied as a lock mass.
Chromatographic analysis was performed using an Aquity 50 × 2.1 mm (i.d.) 1.7 µm UPLC BEH
C18 column (Waters, Milford, MA, USA) with a mobile phase consisting of 0.1% formic acid (A) and
0.1% formic acid in acetonitrile (B). Different linear gradient programs were applied for scouting and
compound-directed chromatography. The longer scouting program applied in the initial studies on
complex mixtures was as follows: 90% A was kept for the first 2 min, then elution from 10 to 100% B
over 25 min with a 10 min hold at 100% B before the eluent was switched back to the initial conditions.
The shorter program was as follows: 98% A kept constant for 2 min, then elution from 2 to 100% B over
3 min and hold at 100% B for 2 min before switching back to the initial conditions. A mobile phase
flow rate of 0.6 mL/min was used, and 2–10 µL samples were injected.
3.3.2. Ultra-Performance Liquid Chromatography Coupled to Photodiode Array Detection
(UPLC-PDA)
The chromatographic features applied in the UPLC-PDA analysis were similar to those described
above (Section 3.3.1), including column type, mobile phase, and elution properties. The UV spectra
were recorded with an Acquity PDA detector (Waters, Milford, MA, USA) between 210 and 600 nm.
The wavelength resolution was 1.2 nm.
3.3.3. NMR Spectroscopy
NMR spectra of compounds 1 and 2 were obtained from solutions (500 µL) in acetonitrile-d3
(CD3CN, 99.96 atom % D; Sigma-Aldrich, St. Louis, MO, USA) using 5 mm o.d. Wilmad tubes
(Sigma-Aldrich, St. Louis, MO, USA). The spectra were acquired on an Avance AVII 600 MHz NMR
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) equipped with a 5 mm CP-TCI triple
resonance inverse cryoprobe with a Z-gradient coil. NMR assignments were obtained from the
examination of 1H, DEPT135, 1-D SELTOCSY, COSY, TOCSY, g-HSQC, g-HMBC, HSQC-TOCSY, and
NOESY NMR spectra. The data were processed using Bruker TOPSPIN (version 2.1 pl4 or version 3)
software. Chemical shifts, determined at 25 ◦C, were reported relative to internal CHD2CN (1.96 ppm)
and CD3CN (118.26 ppm).
3.4. Metabolomics
Diluted SPE-eluates (1 µg/mL) of the species C. decipiens, C. diadema, C. furcellatus, C. karianus,
and C. socialis were analyzed following the protocol described above (Section 3.3.1) in UPLC-MSe in
both ESI positive and negative mode. The chromatograms obtained from the UPLC-MSe analyses
were processed by the MarkerLynx 1.3 application manager (Waters, Milford, MA, USA) for mass
signal extraction and alignment. MarkerLynx makes use of ApexTrack for peak detection and
integration, listing the detected peaks as their m/z values and retention times along with their associated
intensities. When the data are collected, they are automatically delivered to the Extended Statistics
software integrated in MarkerLynx and multivariate statistics are applied for unsupervised principal
components analyses (PCA). The parameters applied in the MarkerLynx application manager were as
follows: XIC windows, 0.02 Da; marker intensity, 1200; mass windows, 0.02 Da; retention window, 0.1;
the Apex Track peak parameters were automatically calculated by MarkerLynx. The isotopes were not
included in the peak detection process.
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4. Conclusions
We have identified two isomeric oxo-fatty acids from Chaetoceros karianus with apparent
dual PPARα/γ agonist activity. These oxo-fatty acids also show a limited isoform-specificity.
(7E)-9-oxohexadec-7-enoic acid mainly activates PPARγ, while (10E)-9-oxohexadec-10-enoic acid
primarily activates PPARα. Principal component analyses indicate that C. karianus differs from other
Chaetoceros species, both with respect to the metabolic profile and the PPAR activity. This finding holds
the potential of defining a PPAR pharmacophore with tunable activity and specificity.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/6/148/s1,
Table S1: PPAR agonist activity found in the Marbank collection.
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